ALSO NOTED: CHMP issues negative opinion on Zavesca;Wyeth CEO discusses the FDA; and much more...

> The Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion for the extension of indication on the use of Actelion's Zavesca. Actelion said it will request a re-examination of the CHMP opinion. Release

> With the FDA in CYA mode, drug makers are having to leap through more hoops to get their products approved--at least that's the opinion of Wyeth CEO Robert Essner and CEO-to-be Bernard Poussot. Report

> The FDA has issued a new warning for three popular ED drugs. Report

> It's an anemia-drug pile-on: Aetna has tightened up its reimbursement rules for Aranesp, Epogen, and Procrit--and analysts believe it will be the first of many private insurers to make the move. Report

> Inspired by Avandia's woes, UK stock analysts are playing a dirge for GlaxoSmithKline's earnings, which are due out next week. Report

> A new imaging probe has highlighted how the human body's hunger pathways operate, illustrating how new therapies could be developed to tame obesity. Report

And Finally... Researchers at UC San Francisco are focusing on a group of genes that not only influence longevity but also reduce the risk of cancer. Report

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.